The market has been down on Minerva Neurosciences Inc (NERV) stock recently. NERV gets a Bearish score from InvestorsObserver's Stock Sentiment Indicator.
What is Stock Sentiment?
Sentiment is a very short-term indicator that is entirely technical. There is no information about the health of profitability of the underlying company in our sentiment score.
As a technical indicator, news about the stock, or company, such as an earnings release or other event, could move the stock counter to the recent trend.
Price action is generally the best indicator of sentiment. For a stock to go up, investors must feel good about it. Similarly, a stock that is in a downtrend must be out of favor.
InvestorsObserver’s Sentiment Indicator considers price action and recent trends in volume. Increasing volumes often mean that a trend is strengthening, while decreasing volumes can signal that a reversal could come soon.
The options market is another place to get signals about sentiment. Since options allow investors to place bets on the price of a stock, we consider the ratio of calls and puts for stocks where options are available.
What's Happening With NERV Stock Today?
Minerva Neurosciences Inc (NERV) stock is down -3.92% while the S&P 500 is higher by 0.48% as of 12:16 PM on Thursday, Mar 4. NERV is lower by -$0.12 from the previous closing price of $3.06 on volume of 633,678 shares. Over the past year the S&P 500 is up 27.79% while NERV is lower by -61.97%. NERV lost -$0.54 per share in the over the last 12 months.
To see InvestorsObserver's Sentiment Score for Minerva Neurosciences Inc click here.
More About Minerva Neurosciences Inc
Minerva Neurosciences Inc is a clinical-stage biopharmaceutical company. The company primarily focuses on the development and commercialization of a portfolio of product candidates to treat patients suffering from central nervous system diseases. Targeted disorders include schizophrenia, insomnia, major depressive disorder and Parkinson's disease. Its product portfolio and potential indications include Roluperidone for the treatment of negative symptoms in patients with schizophrenia; Seltorexant, for the treatment of insomnia disorder and major depressive disorder; MIN-117 for the treatment of MDD; and MIN-301 for the treatment of Parkinson's disease.
Click Here to get the full Stock Score Report on Minerva Neurosciences Inc (NERV) Stock.
